Prevalence of drug –drug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management

ConclusionsClinical interventions on DDI are more frequently required among sarcoma patients treated with TKI than CT. Multidisciplinary risk assessment including a medication reconciliation by a pharmacist could be crucial to prevent DDI with TKI.

http://link.springer.com/10.1007/s00280-021-04311-4

Source: Cancer Chemotherapy and Pharmacology - July 24, 2021 Category: Cancer & Oncology Source Type: research